Scholarlink

Background <p>Problematic benzodiazepine use alongside opioids contributes to drug-related deaths among people who use drugs. Clinical management varies considerably. An intervention to address the root causes of benzodiazepine use with opioids has been developed, which included maintenance prescribing of diazepam with anxiety, sleep, and pain management, harm reduction, and safety conversations. This study tested the feasibility of recruiting and retaining people in the intervention to address ‘street’ benzodiazepine use. Outcome measures and economic evaluation data collection were piloted to determine the feasibility of a future trial.</p> Methods <p>The study tested the intervention in three sites (Grampian, Lothian and Fife) with a target of 15 patients per site. Inclusion criteria were people who were stable on opioid agonist treatment (OAT) with ongoing street benzodiazepine use. The intervention duration was 4–6&#xa0;months depending on the site. Validated tools were used to monitor outcomes covering: anxiety (GAD-7), depression (PHQ-9), quality of life (EQ-5D-5L), substance use recovery (SURE), and cognitive function (ACE-III). ‘Street’ drug use was measured through oral fluid tests and self-report. Resource use data were collected from an NHS perspective using a bespoke questionnaire to inform a future economic evaluation.</p> Results <p>After revisions to the inclusion criteria, 39 people were recruited (9 women, 30 men), mean age: 42 yrs. Almost all had diagnosed anxiety (<i>n</i> = 38) and depression (<i>n</i> = 39,); sleep problems were common (<i>n</i> = 34), and over half had chronic pain (<i>n</i> = 21). Retention was 77% at final data collection at 4–6&#xa0;months (<i>n</i> = 30). There were indications of improvement in anxiety, depression, self-reported recovery, and quality of life. Cognitive function was stable. Self-reported ‘street’ benzodiazepine use reduced from 100% (<i>n</i> = 39) at baseline to 35% at follow-up (<i>n</i> = 10).</p> <p>The economic data indicated good completion of the resource use and quality of life questionnaires, but this was dependent on the participants attending clinic appointments.</p> Conclusion <p>Recruitment was feasible, and there were signs of clinical improvements across anxiety, depression, quality of life, and recovery measures. Findings justify a randomised controlled trial of this intervention vs. standard care of a benzodiazepine tapering dose. However, accurate, objective measurement of current ‘street’ drug use is required.</p> Trial registration <p>ISRCTN number: 95130898. Registered 23/10/2023—retrospectively registered; ethical approval: approved 29/10/2021, North of Scotland Ethics Committee, ref: 21/NS/0135.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A feasibility study of a co-designed intervention to manage benzodiazepine dependence and high-risk use in those receiving opioid agonist treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Catriona Matheson,
  • Karen Berry,
  • Mary Kilonzo,
  • Susanna Galea-Singer,
  • Duncan Hill,
  • Trina Ritchie,
  • Joe Schofield,
  • Duncan Stewart,
  • Michael Turner,
  • Graeme MacLennan

摘要

Background

Problematic benzodiazepine use alongside opioids contributes to drug-related deaths among people who use drugs. Clinical management varies considerably. An intervention to address the root causes of benzodiazepine use with opioids has been developed, which included maintenance prescribing of diazepam with anxiety, sleep, and pain management, harm reduction, and safety conversations. This study tested the feasibility of recruiting and retaining people in the intervention to address ‘street’ benzodiazepine use. Outcome measures and economic evaluation data collection were piloted to determine the feasibility of a future trial.

Methods

The study tested the intervention in three sites (Grampian, Lothian and Fife) with a target of 15 patients per site. Inclusion criteria were people who were stable on opioid agonist treatment (OAT) with ongoing street benzodiazepine use. The intervention duration was 4–6 months depending on the site. Validated tools were used to monitor outcomes covering: anxiety (GAD-7), depression (PHQ-9), quality of life (EQ-5D-5L), substance use recovery (SURE), and cognitive function (ACE-III). ‘Street’ drug use was measured through oral fluid tests and self-report. Resource use data were collected from an NHS perspective using a bespoke questionnaire to inform a future economic evaluation.

Results

After revisions to the inclusion criteria, 39 people were recruited (9 women, 30 men), mean age: 42 yrs. Almost all had diagnosed anxiety (n = 38) and depression (n = 39,); sleep problems were common (n = 34), and over half had chronic pain (n = 21). Retention was 77% at final data collection at 4–6 months (n = 30). There were indications of improvement in anxiety, depression, self-reported recovery, and quality of life. Cognitive function was stable. Self-reported ‘street’ benzodiazepine use reduced from 100% (n = 39) at baseline to 35% at follow-up (n = 10).

The economic data indicated good completion of the resource use and quality of life questionnaires, but this was dependent on the participants attending clinic appointments.

Conclusion

Recruitment was feasible, and there were signs of clinical improvements across anxiety, depression, quality of life, and recovery measures. Findings justify a randomised controlled trial of this intervention vs. standard care of a benzodiazepine tapering dose. However, accurate, objective measurement of current ‘street’ drug use is required.

Trial registration

ISRCTN number: 95130898. Registered 23/10/2023—retrospectively registered; ethical approval: approved 29/10/2021, North of Scotland Ethics Committee, ref: 21/NS/0135.